Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 14/20 | 0.45 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5398885 | 0.86 | NPBWR1 (0.45) | PDE5ANPBWR1 | |
| SCHEMBL6656130 | 0.85 | PDE5A (0.41) | PDE5ANPBWR1PDE3BPDE3ALMNA | |
| SCHEMBL5407983 | 0.85 | NPBWR1 (0.42) | PDE5ANPBWR1PDE3BPDE3A | |
| SCHEMBL5395967 | 0.79 | NPBWR1 (0.41) | PDE5ANPBWR1 | |
| SCHEMBL5404511 | 0.79 | NPBWR1 (0.40) | PDE5ANPBWR1LMNA | |
| SCHEMBL5404242 | 0.79 | XIAP (0.46) | PDE5ANPBWR1 | |
| SCHEMBL5398879 | 0.78 | NPBWR1 (0.43) | PDE5ANPBWR1 | |
| SCHEMBL5395271 | 0.73 | SLC16A1 (0.49) | PDE5APDE3BPDE3ALMNA | |
| SCHEMBL5394043 | 0.70 | SLC16A1 (0.52) | PDE5APDE3BPDE3ALMNA | |
| SCHEMBL5400640 | 0.70 | SLC16A1 (0.54) | PDE5APDE3BPDE3ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | DPYD, HPGDS, PGC | PDE5A 933/4885NPBWR1 3728/4885PDE3B 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.